Bladder Cancer

Roger Li, MD, spoke about responses from the CORE1 trial that examined patients with non–muscle invasive bladder cancer treated with CG0070 plus pembrolizumab.

Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Expert panelists focus on the treatment of metastatic urothelial cancer and discuss strategies and challenges for maintenance therapy.

A manageable safety profile and good clinical activity were observed with toripalimab in Chinese patients with urothelial carcinoma.

An exploratory analysis of the JAVELIN Bladder 100 study indicated long-term overall survival benefit for patients with advanced urothelial carcinoma who received avelumab maintenace, without regard for treatment given in the second-line setting.

Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.

Results of the COSMIC-021 trial presented at ASCO 2022 show promise of cabozantinib plus atezolizumab for urothelial carcinoma.

Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

Patients with upper tract urothelial carcinoma may benefit from treatment with oral FGFR1-3 inhibitor infigratinib.

Neoadjuvant atezolizumab as a treatment for muscle-invasive urothelial cancer of the bladder yielded a high disease-free survival.

Awareness of smoking as a risk factor for bladder cancer is lower compared with other smoking-related conditions, highlighting a need for further education in urology.

Patients with untreated unresectable or metastatic urothelial carcinoma and PD-L1 expression of 1% or more who received treatment with nivolumab and ipilimumab in the first-line setting did not experience an improved overall survival vs those getting standard-of-care chemotherapy, according to a final analysis of a phase 3 trial.

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.